TY - CHAP
T1 - Heterogeneity of head and neck squamous cell carcinoma stem cells
AU - Qian, Xu
AU - Nie, Xiaobo
AU - Wollenberg, Barbara
AU - Sudhoff, Holger
AU - Kaufmann, Andreas M.
AU - Albers, Andreas E.
N1 - Publisher Copyright:
© Springer Nature Switzerland AG 2019.
PY - 2019
Y1 - 2019
N2 - Current systemic cancer treatment in head and neck squamous cell carcinoma (HNSCC) is moving toward more personalized approaches such as de-escalation protocols human-papilloma-virus dependent HNSCC or application of checkpoint inhibitors. However, these treatments have been challenged by cancer stem cells (CSC), a small population within the bulk tumor, which are leading to treatment failure, tumor recurrence, or metastases. This review will give an overview of the characteristics of HNSCC-CSC. Specifically, the mechanisms by which HNSCC-CSC induce tumor initiation, progression, recurrence, or metastasis will be discussed. Although evidence-based treatment options targeting HNSCC-CSC specifically are still being sought for, they warrant a promise for additional and sustainable treatment options where for HNSCC patients where others have failed.
AB - Current systemic cancer treatment in head and neck squamous cell carcinoma (HNSCC) is moving toward more personalized approaches such as de-escalation protocols human-papilloma-virus dependent HNSCC or application of checkpoint inhibitors. However, these treatments have been challenged by cancer stem cells (CSC), a small population within the bulk tumor, which are leading to treatment failure, tumor recurrence, or metastases. This review will give an overview of the characteristics of HNSCC-CSC. Specifically, the mechanisms by which HNSCC-CSC induce tumor initiation, progression, recurrence, or metastasis will be discussed. Although evidence-based treatment options targeting HNSCC-CSC specifically are still being sought for, they warrant a promise for additional and sustainable treatment options where for HNSCC patients where others have failed.
KW - Aldehyde dehydrogenase I
KW - CSC-directed therapeutic
KW - Cancer stem cell (CSC)
KW - Epidermal growth factor receptor (EGFR)
KW - Epithelial-to-mesenchymal transition (EMT)
KW - Head and neck squamous cell carcinoma (HNSCC)
KW - Immune evasion
KW - Immune response
KW - Immunotherapy
KW - Mesenchymal-to-epithelial transition (MET)
KW - PD-1
KW - PD-L1
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85066265848&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-14366-4_2
DO - 10.1007/978-3-030-14366-4_2
M3 - Chapter
C2 - 31134493
AN - SCOPUS:85066265848
T3 - Advances in Experimental Medicine and Biology
SP - 23
EP - 40
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -
